Carlsmed Q4 revenue surges, driven by AI-enabled spine surgery solutions

Carlsmed

25/02/2026 21:16

Overview

Medical technology firm's Q4 revenue grew 61% yr/yr

Company reported Q4 net loss of $8.6 mln

Company launched new cervical and bilateral fusion systems

Outlook

Carlsmed expects 2026 revenue between $70 mln and $75 mln

Result Drivers

REVENUE GROWTH - Carlsmed reported a 61% increase in Q4 revenue, driven by scaling of AI-enabled spine surgery solutions

GROSS MARGIN EXPANSION - Gross margin improved to 76.5% in Q4, reflecting operational efficiencies

Company press release: ID:nGNX482rTG

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$8.60 mln
Q4 Adjusted EBITDA
-$8.40 mln
Q4 Gross Margin
76.50%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Carlsmed Inc is $18.00, about 37.8% above its February 24 closing price of $13.06

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)